Top

Clinical Orthopaedics and Related Research®

Published in:

01-11-2011 | Basic Research

Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro

Authors: Berna Kankilic, MS, Erdal Bayramli, PhD, Emine Kilic, MS, Sezin Dağdeviren, MS, Feza Korkusuz, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 11/2011

Abstract

Background

Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/β-tricalcium phosphate (PLLA/β-TCP) composite to control antibiotic release and stimulate bone formation.

Questions/purposes

We (1) characterized these composites, (2) assessed vancomycin release in inhibitory doses, and (3) determined whether they would permit cell adhesion, proliferation, and mineralization in vitro.

Methods

We molded 250 vancomycin-containing (VC) and 125 vancomycin-free (VUC) composites using PLLA, β-TCP, and chloroform. One hundred twenty-five VC composites were further dip-coated with PLLA (CVC) to delay antibiotic release. Composites were characterized according to their pore structure, size, volume, density, and surface area. Vancomycin release and bioactivity were determined. Adhesion, proliferation, and mineralization were assessed for two and three replicates on Days 3 and 7 with mesenchymal stem (MSC) and Saos type 2 cells.

Results

Pore size, volume, apparent density, and surface area of the CVC were 3.5 ± 1.9 μm, 0.005 ± 0.002 cm³/g, 1.18 g/cm³ and 3.68 m²/g, respectively. CVC released 1.71 ± 0.13 mg (63.1%) and 2.49 ± 0.64 mg (91.9%) of its vancomycin on Day 1 and Week 6, respectively. MSC and Saos type 2 cells attached and proliferated on composites on Days 3 and 7.

Conclusions

Vancomycin-containing PLLA/β-TCP composites release antibiotics in inhibitory doses after dip coating and appeared biocompatible based on adhesion, proliferation, and mineralization.

Clinical Relevance

Vancomycin-containing PLLA/β-TCP composites may be useful for controlling MRSA but will require in vivo confirmation.

Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro an in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res. 1992;278:244–252.PubMed

Antoci V Jr, Adams CS, Parvizi J, Davidson HM, Composto RJ, Freeman TA, Wickstrome E, Ducheyne P, Jungkind D, Shapiro IM, Hickok NJ. The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin modified titanium alloy and implications for the treatment of periprosthetic infection. Biomaterials. 2008;29:4684–4690.PubMedCrossRef

Aslam S, Darouiche RO. Antimicrobial therapy for bone and joint infections. Curr Infect Dis Rep. 2009;11:7–13.PubMedCrossRef

Aunoble S, Clement D, Frayssinet P, Harmand MF, Le Huec JC. Biological performance of a new β-TCP/PLLA composite material for applications in spine surgery: in vitro and in vivo studies. J Biomed Mater Res A. 2006;78:416–422.PubMed

Broz A, Baresova V, Kromka A, Rezek B, Kalbacova M. Strong influence of hierarchically structured diamond nanotopography on adhesion of human osteoblasts and mesenchymal cells. Physica Status Solidi A. 2009;206:2038–2041.CrossRef

Bryers JD. Medical biofilms. Biotechnol Bioeng. 2008;100:1–18.PubMedCrossRef

Cabanas MV, Pena J, Roman J, Vallet-Regi M. Tailoring vancomycin release from β-TCP/agarose scaffolds. Eur J Pharm Sci. 2009;37:249–256.PubMedCrossRef

Cevher E, Orhan Z, Mulazimoglu L, Sensoy D, Alper M, Yildiz A, Ozsoy Y. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres. Int J Pharm. 2006;317: 127–135.PubMedCrossRef

Chen Y, Cho MR, Mak AFT, Li JS, Wang M, Sun S. Morphology and adhesion of mesenchymal stem cells on PLLA, apatite and apatite/collagen surfaces. J Mater Sci Mater Med. 2008;19:2563–2567.PubMedCrossRef

10.

Cierny G 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7–24.PubMedCrossRef

11.

Dash AK, Cudworth GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998;40:1–12.PubMedCrossRef

12.

Dion A, Langman M, Hall G, Filiaggi M. Vancomycin release behavior from amorphous calcium polyphosphate matrices intended for osteomyelitis treatment. Biomaterials. 2005;26:7276–7285.PubMedCrossRef

13.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317.PubMedCrossRef

14.

Esposito S, Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int J Antimicrob Agents. 2008;32:287–293.PubMedCrossRef

15.

Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res. 2006;437:105–110.

16.

Gbureck U, Vorndran E, Barralet JE. Modeling vancomycin release kinetics from microporous calcium phosphate ceramics comparing static and dynamic immersion conditions. Acta Biomater. 2008;4:1480–1486.PubMedCrossRef

17.

Gursel I, Yagmurlu F, Korkusuz F, Hasirci V. In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods. J Microencapsul. 2002;19:153–164.CrossRef

18.

Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes Metab. 2008;34:87–95.PubMedCrossRef

19.

Hendriks JG, van Horn JR, van der Mei HC, Busscher HJ. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials. 2004;25:545–556.PubMedCrossRef

20.

Jager M, Feser T, Denck H, Krauspe R. Proliferation and osteogenic differentiation of mesenchymal stem cells cultured onto three different polymers in vitro. Ann Biomed Eng. 2005;33:1319–1332.PubMedCrossRef

21.

Kanellakopoulou K, Giamerallos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59:1223–1232.PubMedCrossRef

22.

Kluin OS, van der Mei HC, Busscher HJ, Neut D. A surface-eroding antibiotic delivery system based on poly-(trimethylene carbonate). Biomaterials. 2009;30:4738–4742.PubMedCrossRef

23.

Koç N, Timuçin M, Korkusuz F. Fabrication and characterization of porous tricalcium phosphate ceramics. Ceramics Int. 2004;30:205–211.CrossRef

24.

Korkusuz F, Uchida A, Shinto Y, Inoue K, Ono K. Biomaterial centered chronic osteomyelitis. Turk J Med Res. 1992;10:268–292.

25.

Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007;120:13–20.CrossRef

26.

Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP, Lipsky BA. Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Res Clin Pract. 2009;83:347–352.PubMedCrossRef

27.

Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364: 369–379.PubMedCrossRef

28.

Li H, Ogle H, Jiang B, Hagar M, Li B. Cefazolin embedded biodegradable polypeptide nanofilms promising for infection prevention: a preliminary study on cell responses. J Orthop Res. 2010;28:992–999.PubMedCrossRef

29.

Liu SJ, Ueng SW, Lin S, Chan E. In vivo release of vancomycin from biodegradable beads. J Biomed Mater Res. 2002;63:807–813.PubMedCrossRef

30.

Lucke M, Schmidmaier G, Sadoni S, Wildemann B, Schiller R, Haas NP, Raschke M. 2003. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone. 2003;32:521–531.PubMedCrossRef

31.

Mamidwar SS, Arena C, Kelly S, Alexander H, Ricci J. In vitro characterization of a calcium sulfate/PLLA composite for use as a bone graft material. J Biomed Mater Res B Appl Biomater. 2007;81:57–65.PubMed

32.

Merten HA, Wiltfang J, Grohmann U, Hoenig JF. Intraindividual comparative animal study of α- and β-tricalcium phosphate degradation in conjunction with simultaneous insertion of dental implants. J Craniofac Surg. 2001;12:59–68.PubMedCrossRef

33.

Miyai T, Ito A, Tamazawa G, Matsuno T, Sogo Y, Nakamura C, Yamazaki A, Satoh T. Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis. Biomaterials. 2008;29:350–358.PubMedCrossRef

34.

Montjovent MO, Mark S, Mathieu L, Scaletta C, Scherberich A, Delabarde C, Zambelli PY, Bourban PE, Applegate LA, Pioletti DP. Human fetal bone cells associated with ceramic reinforced PLA scaffolds for tissue engineering. Bone. 2008;42:554–564.PubMedCrossRef

35.

Nandi KS, Kundu B, Ghosh SK, Mandal TK, Datta S, De DK, Basu D. Cefuroxime-impregnated calcium phosphates as an implantable delivery system in experimental osteomyelitis. Ceramics Int. 2009;35:1367–1376CrossRef

36.

Noel SP, Courtney H, Bumgardner JD, Haggard WO. Chitosan films: a potential local drug delivery system for antibiotics. Clin Orthop Relat Res. 2008;466:1377–1382.PubMedCrossRef

37.

Petrone C, Hall G, Langman M, Filiaggi MJ. Compaction strategies for modifying the drug delivery capabilities of gelled calcium polyphosphate matrices. Acta Biomater. 2008;4:403–413.PubMedCrossRef

38.

Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27:3413–3431.PubMedCrossRef

39.

Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.PubMedCrossRef

40.

Schmidmaier G, Lucke M, Wildemann B, Haas NP, Raschke M. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury. 2006;37:105–112.CrossRef

41.

Schofield SC, Berno B, Langman M, Hall G, Filiaggi MJ. Gelled calcium polyphosphate matrices delay antibiotic release. J Dent Res. 2006;85:643–647.PubMedCrossRef

42.

Senthi S, Munro JT, Pitto RP. Infection in total hip replacement: meta-analysis. Int Orthop. 2011;35:253–260.PubMedCrossRef

43.

Shikhar Vohra S, Hennessy KM, Sawyer AA, Zhuo Y, Bellis SL. Comparison of mesenchymal stem cell and osteosarcoma cell adhesion to hydroxyapatite. J Mater Sci Mater Med. 2008;19:3567–3574.PubMedCrossRef

44.

Sia IG, Berbari EF. Osteomyelitis. Best Pract Res Clin Rheumatol. 2006;20:1065–1081.PubMedCrossRef

45.

Tanaka KS, Dietrich E, Ciblat S, Métayer C, Arhin FF, Sarmiento I, Moeck G, Parr TR Jr, Far AR. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorg Med Chem Lett. 2010;20:1355–1359.PubMedCrossRef

46.

Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O’Hara CM, McAllister SK, Clark NC, Hiramatsu K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 1998;36:1020–1027.PubMed

47.

Webb ND, McCanless JD, Courtney HS, Bumgardner JD, Haggard WO. Daptomycin eluted from calcium sulfate appears effective against Staphylococcus. Clin Orthop Relat Res. 2008;466:1383–1387.PubMedCrossRef

48.

Yagmurlu MF, Korkusuz F, Gursel I, Korkusuz P, Ors U, Hasirci V. Sulbactam-cefoperazone polyhydroxybutyrate-cohydroxyvalerate (PHBV) local antibiotic delivery system: in vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis. J Biomed Mater Res. 1999;46:494–503.PubMedCrossRef

49.

Zimmerli W. Infection and musculoskeletal conditions: prosthetic-joint-associated infections. Best Pract Res Clin Rheumatol. 2006;20:1045–1063.PubMedCrossRef

Title: Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro
Authors: Berna Kankilic, MS
Erdal Bayramli, PhD
Emine Kilic, MS
Sezin Dağdeviren, MS
Feza Korkusuz, MD
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Clinical Orthopaedics and Related Research® / Issue 11/2011
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-011-2082-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vancomycin Containing PLLA/β-TCP Controls MRSA In Vitro

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Clinical Relevance

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Clinical Relevance

Please log in to get access to this content

Other articles of this Issue 11/2011

The Classic: On the Significance of the Architecture of the Spongy Substance for the Question of Bone Growth: A preliminary publication

Human Early Fracture Hematoma Is Characterized by Inflammation and Hypoxia

Two-stage Exchange Arthroplasty for Infected Total Knee Arthroplasty: Predictors of Failure

Validity of Goniometric Elbow Measurements: Comparative Study with a Radiographic Method

Biographical Sketch: Georg Hermann von Meyer (1815–1892)

Erratum to: Papers Presented at the 2009 Meeting of the Musculoskeletal Infection Society: Editorial Comment